BASF

Last updated January 31, 2026

319

Innovation Areas

13,244

Inventors

154

Collaborations

Multi-target bioactive molecular formulations: BASFRecent Research Landscape

Metabolic instability and poor bioavailability of natural lipids limit their therapeutic efficacy in chronic inflammatory conditions. These innovations engineer specific oxygen-containing substitutions to enhance metabolic half-life and glycemic signaling.

What technical problems is BASF addressing in Multi-target bioactive molecular formulations?

Poor gastrointestinal lipid bioavailability

(3)evidences

Chronic cellular damage and impaired glucose regulation in hepatic and intestinal tissues. Resolving these pathologies prevents irreversible organ scarring and systemic metabolic failure.